Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
86 hedge funds and large institutions have $235M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 13 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
46% more call options, than puts
Call options by funds: $383K | Put options by funds: $262K
3% less funds holding
Funds holding: 89 → 86 (-3)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
26% less capital invested
Capital invested by funds: $317M → $235M (-$81.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$8.37M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.43M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$3.21M |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$962K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$643K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$9.19M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$1.75M |
| 3 |
JP Morgan Chase
New York
|
-$1.43M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.37M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.11M |
RETA Hedge Fund Activity: Q1 2018 in Review
86 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q1 2018, worth a combined $235M — down 26% from $317M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of RETA and 11 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 32 added.
The largest buyer was Boxer Capital, opening a new position worth an estimated $8.37M. The largest seller was Laurion Capital Management, cutting an estimated $9.19M.
- 86 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q1 2018, down from 89 in Q4 2017.
- Funds reported $235M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q1 2018, down 26% quarter-over-quarter.
- 11 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q1 2018 and 13 closed out, a net change of -2 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q1 2018 was Boxer Capital, an estimated $8.37M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q1 2018 was Laurion Capital Management, an estimated $9.19M sold.
Based on aggregated 13F filings for Q1 2018.